Study of the early occurrence of hepatocellular carcinoma (HCC) in Egyptian HCV infected patients receiving Sofosbuvir and Daclatasvir

Abstract

Hepatitis C virus infection is a highly prevalent disease all over the world. HCV has many genotypes. The dominant genotype in Egypt is genotype 4. HCV causes acute and chronic hepatitis C. The DAAs were discovered in 2011 with evolutionary efficacy against HCV. This discovery raises the global hope of HCV eradication. Many patients developed HCC after HCV eradication, which raised a question about whether DAAs can be the cause of hepatocellular carcinoma or not. So this study was conducted to detect the incidence of HCC among CHC patients treated with different DAAs regimens. One hundred and forty-five patients were included in this observational study. The included patient had a positive HCV-RNA test. The patients were classified into two groups according to the treatment they received. The first group who was treated with Sofosbuvir and Daclatasvir “easy to treat group” [S/D group] and the second group who was treated with Sofosbuvir, Daclatasvir, and Ribavirin “difficult to treat group” [S/D/R group]. It was found that six patients (three males and three females) from the S/D/R group were diagnosed with HCC